Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked higher than
98% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. SGEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SGEN' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6548
N/A
No Debt
Equity to Asset 0.77
SGEN's Equity to Asset is ranked higher than
61% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SGEN: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
SGEN' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.58 Max: 0.96
Current: 0.77
0.36
0.96
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
97% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SGEN' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 12.55
M-Score: -1.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -38.89
SGEN's Operating margin (%) is ranked higher than
57% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. SGEN: -38.89 )
Ranked among companies with meaningful Operating margin (%) only.
SGEN' s Operating margin (%) Range Over the Past 10 Years
Min: -401.85  Med: -157.83 Max: -23.35
Current: -38.89
-401.85
-23.35
Net-margin (%) -38.51
SGEN's Net-margin (%) is ranked higher than
57% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. SGEN: -38.51 )
Ranked among companies with meaningful Net-margin (%) only.
SGEN' s Net-margin (%) Range Over the Past 10 Years
Min: -359.97  Med: -158.80 Max: -23.22
Current: -38.51
-359.97
-23.22
ROE (%) -40.20
SGEN's ROE (%) is ranked lower than
57% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. SGEN: -40.20 )
Ranked among companies with meaningful ROE (%) only.
SGEN' s ROE (%) Range Over the Past 10 Years
Min: -128.57  Med: -40.02 Max: -24.17
Current: -40.2
-128.57
-24.17
ROA (%) -22.66
SGEN's ROA (%) is ranked higher than
54% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. SGEN: -22.66 )
Ranked among companies with meaningful ROA (%) only.
SGEN' s ROA (%) Range Over the Past 10 Years
Min: -50.86  Med: -28.26 Max: -12
Current: -22.66
-50.86
-12
ROC (Joel Greenblatt) (%) -276.57
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. SGEN: -276.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -903.49  Med: -523.09 Max: -178.02
Current: -276.57
-903.49
-178.02
Revenue Growth (3Y)(%) 40.30
SGEN's Revenue Growth (3Y)(%) is ranked higher than
88% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. SGEN: 40.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.3  Med: 39.90 Max: 157.1
Current: 40.3
7.3
157.1
EBITDA Growth (3Y)(%) -24.70
SGEN's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. SGEN: -24.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.2  Med: -1.65 Max: 18
Current: -24.7
-30.2
18
EPS Growth (3Y)(%) -22.90
SGEN's EPS Growth (3Y)(%) is ranked lower than
73% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SGEN: -22.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.2  Med: -4.75 Max: 27.7
Current: -22.9
-34.2
27.7
» SGEN's 10-Y Financials

Financials (Next Earnings Date: 2016-02-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SGEN Guru Trades in Q1 2015

PRIMECAP Management 11,836,575 sh (+5.89%)
Manning & Napier Advisors, Inc 492,690 sh (+1.42%)
Columbia Wanger 3,408,200 sh (-23.82%)
» More
Q2 2015

SGEN Guru Trades in Q2 2015

Vanguard Health Care Fund 170,125 sh (New)
PRIMECAP Management 11,899,100 sh (+0.53%)
Columbia Wanger 2,355,005 sh (-30.90%)
Manning & Napier Advisors, Inc 252,470 sh (-48.76%)
» More
Q3 2015

SGEN Guru Trades in Q3 2015

Paul Tudor Jones 22,173 sh (New)
John Burbank 159,966 sh (New)
Jim Simons 15,880 sh (New)
Ray Dalio 36,000 sh (New)
PRIMECAP Management 12,865,950 sh (+8.13%)
Manning & Napier Advisors, Inc 252,470 sh (unchged)
Manning & Napier Advisors, Inc 252,470 sh (unchged)
Vanguard Health Care Fund 170,125 sh (unchged)
Columbia Wanger 1,842,396 sh (-21.77%)
» More
Q4 2015

SGEN Guru Trades in Q4 2015

Vanguard Health Care Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Seattle Genetics Inc

Vanguard Health Care Fund Buys 2 New Stakes in Second Quarter
As its name suggests, Vanguard Health Care Fund (Trades, Portfolio) invests almost exclusively in health care companies. It’s been a successful investment niche. Vanguard enjoyed returns exceeding 28% in 2014, 43% in 2013 and 15% in 2012. Read more...

Ratios

vs
industry
vs
history
P/B 6.38
SGEN's P/B is ranked lower than
87% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. SGEN: 6.38 )
Ranked among companies with meaningful P/B only.
SGEN' s P/B Range Over the Past 10 Years
Min: 1.74  Med: 8.68 Max: 36.09
Current: 6.38
1.74
36.09
P/S 12.54
SGEN's P/S is ranked lower than
59% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. SGEN: 12.54 )
Ranked among companies with meaningful P/S only.
SGEN' s P/S Range Over the Past 10 Years
Min: 9.98  Med: 19.93 Max: 45.83
Current: 12.54
9.98
45.83
EV-to-EBIT -30.00
SGEN's EV-to-EBIT is ranked lower than
99.99% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. SGEN: -30.00 )
Ranked among companies with meaningful EV-to-EBIT only.
SGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -102.6  Med: -12.20 Max: -2.8
Current: -30
-102.6
-2.8
EV-to-EBITDA -33.88
SGEN's EV-to-EBITDA is ranked lower than
99.99% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. SGEN: -33.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -120.2  Med: -12.80 Max: -3.1
Current: -33.88
-120.2
-3.1
Current Ratio 6.65
SGEN's Current Ratio is ranked higher than
61% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. SGEN: 6.65 )
Ranked among companies with meaningful Current Ratio only.
SGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.65  Med: 5.23 Max: 30.03
Current: 6.65
2.65
30.03
Quick Ratio 6.30
SGEN's Quick Ratio is ranked higher than
61% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. SGEN: 6.30 )
Ranked among companies with meaningful Quick Ratio only.
SGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.29  Med: 5.02 Max: 30.03
Current: 6.3
2.29
30.03
Days Inventory 442.64
SGEN's Days Inventory is ranked lower than
94% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 124.17 vs. SGEN: 442.64 )
Ranked among companies with meaningful Days Inventory only.
SGEN' s Days Inventory Range Over the Past 10 Years
Min: 442.93  Med: 557.12 Max: 639.76
Current: 442.64
442.93
639.76
Days Sales Outstanding 72.96
SGEN's Days Sales Outstanding is ranked lower than
56% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. SGEN: 72.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.55  Med: 61.69 Max: 562.77
Current: 72.96
25.55
562.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.45
SGEN's Price/Net Cash is ranked lower than
60% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. SGEN: 8.45 )
Ranked among companies with meaningful Price/Net Cash only.
SGEN' s Price/Net Cash Range Over the Past 10 Years
Min: 2.12  Med: 10.58 Max: 284.71
Current: 8.45
2.12
284.71
Price/Net Current Asset Value 6.92
SGEN's Price/Net Current Asset Value is ranked lower than
57% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. SGEN: 6.92 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGEN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.09  Med: 9.59 Max: 447
Current: 6.92
2.09
447
Price/Tangible Book 6.38
SGEN's Price/Tangible Book is ranked lower than
64% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. SGEN: 6.38 )
Ranked among companies with meaningful Price/Tangible Book only.
SGEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.78  Med: 5.73 Max: 33.85
Current: 6.38
1.78
33.85
Price/Median PS Value 0.63
SGEN's Price/Median PS Value is ranked higher than
70% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SGEN: 0.63 )
Ranked among companies with meaningful Price/Median PS Value only.
SGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 1.13 Max: 28.5
Current: 0.63
0.52
28.5
Earnings Yield (Greenblatt) (%) -3.30
SGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. SGEN: -3.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3.34  Med: 0.00 Max: 0
Current: -3.3
-3.34
0

More Statistics

Revenue(Mil) $318
EPS $ -0.98
Beta2.01
Short Percentage of Float29.47%
52-Week Range $29.31 - 52.33
Shares Outstanding(Mil)139.48

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 331 414 525 738
EPS($) -0.91 -0.49 -0.18 0.66
EPS without NRI($) -0.91 -0.49 -0.18 0.66

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SGT.Germany,
Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. In August 2011, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of ADCETRIS, or brentuximab vedotin, in two indications; the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant, or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma, or sALCL, after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Companys proprietary technology. The Company collaborated with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS. The Company has a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy in patients with Hodgkin lymphoma and sALCL and other CD30-positive malignancies. In addition, it has five clinical-stage ADC programs, which consist of SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. It includes pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 

More From Other Websites
[$$] Today's Top 5 Stock Picks: Solid Profits, Discounted Feb 04 2016
Coverage initiated on Seattle Genetics by Barclays Feb 04 2016
8:05 am Seattle Genetics will receive a one-time $20 million milestone payment under its ADCETRIS w/... Feb 04 2016
Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin)... Feb 04 2016
Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date? Feb 01 2016
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 29 2016
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2015... Jan 20 2016
This Biotech CEO Made Investors 7x On His Last Deal Jan 12 2016
Biotech Exec Took A Company From $2 to $14, Before Starting On This New Deal Jan 12 2016
Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : January 5, 2016 Jan 05 2016
Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 Jan 05 2016
Seattle Genetics to Present at the J.P. Morgan Healthcare Conference Jan 05 2016
Seattle Genetics to Present at the J.P. Morgan Healthcare Conference Jan 05 2016
Seattle Genetics/Bristol-Myers Begin Adcetris-Opdivo Study Dec 24 2015
Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of... Dec 23 2015
Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of... Dec 23 2015
Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of... Dec 23 2015
Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : December 17, 2015 Dec 17 2015
The Smart Money Is Hoarding Shares of These 10 Healthcare Stocks: Part 1 Dec 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK